Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CG Oncology, Inc. - Common stock (NQ:CGON)

41.46 -0.39 (-0.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CG Oncology, Inc. - Common stock

< Previous 1 2 3 Next >
Why Cg Oncology Stock Rocketed 7% Higher Today
One pundit believes this is a clinical-stage company well worth watching. 
Via The Motley Fool
CG Oncology Stock Signals Bullish Momentum Ahead
CG Oncology has entered its Phase 2 of the Adhishthana Cycle, signaling a bullish setup. With momentum already building, here's what to track... 
Via Benzinga
CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Completes Enrollment in PIVOT-006
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences
From CG Oncology Inc.
Via GlobeNewswire
Cg Oncology (CGON) Q2 Loss Widens 93%
Via The Motley Fool
CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals
From CG Oncology Inc.
Via GlobeNewswire
Which stocks are moving before the opening bell on Tuesday?
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Beyond The Numbers: 7 Analysts Discuss CG Oncology Stock
 
Via Benzinga
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
Via Investor Brand Network
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:REGN),(NASDAQ:VRTX),(OTCQX:RHHBY),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Cancer Rates Are Surging in Young Adults — Here’s Where the Smart Money Is Going
Issued on behalf of Oncolytics Biotech Inc. Vancouver, BC – June 18, 2025 – USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer.... 
Via FinancialNewsMedia
CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
Pony AI, Hims & Hers And Frontdoor Are Among Top 11 Mid-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
Top performers last week: PONY, HIMS, ODD, MTSR, CGON, KNSA, KC, FTDR, ATI, PRDO, and IRTC. Have you invested in them? 
Via Benzinga
Topics Artificial Intelligence
SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
From CG Oncology Inc.
Via GlobeNewswire
These stocks are moving in today's session
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook
 
Via Benzinga
Which stocks are gapping on Monday?
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why
CG Oncology shared new Phase 3 trial results showing durable responses and strong patient compliance in high-risk bladder cancer treatment at AUA 2025. 
Via Benzinga
These stocks are moving in today's pre-market session
Wondering what's happening in Monday's pre-market session? Find an overview in this article. 
Via Chartmill
Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug
The companies are working on treatments for a form of bladder cancer. 
Via Investor's Business Daily
Dow Jumps Over 150 Points; Domino's Pizza Posts Upbeat Earnings
 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
From CG Oncology Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.